This study aimed to investigate the demographics, treatment outcomes, and prognostic factors of salvage endoscopic nasopharyngectomy in recurrent nasopharyngeal carcinoma (NPC).
Methods
We conducted a retrospective analysis of 189 patients who underwent treatment for recurrent NPC from January 2006 to June 2018. The Kaplan–Meier method and log-rank test were used to assess survival rates. A Cox regression model was used for multivariate survival analyses.
Results
We included 132 men and 57 women in the study, with a median age of 51 (range, 25–85) years. The overall 1-, 3-, and 5-year survival rates were 82.2%, 59.5%, and 43.6%, respectively, during a median follow-up of 24 (range, 2–111) months. In subjects over 50 years of age, diabetes, low body mass index (BMI < 20 kg/m2), low hemoglobin (<120 g/l) levels, increased neutrophil to lymphocyte ratio (NLR; ≥ 6), advanced T stage (rT3 and rT4), lymph node metastasis, and positive surgical margins were associated with a poor prognosis in terms of overall survival. Cox multivariate regression analyses showed significant differences in age, BMI, NLR, diabetes, T stage, N stage, and tumor necrosis.
Conclusions
In subjects over 50 years of age, diabetes, low BMI, increased NLR, advanced T stage, lymph node metastasis, and tumor necrosis were independent prognostic factors for overall survival.
YuMCYuanJM.Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol. 2002;
12(6):421–429.
2.
YuKHLeungSFTungSY, et al. Hong Kong Nasopharyngeal Carcinoma Study Group.
Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong nasopharyngeal carcinoma study group. Head Neck. 2005;
27(5):397–405.
3.
YouRZouXHuaYJ, et al.
Salvage endoscopic nasopharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1-T3 nasopharyngeal carcinoma—a case-matched comparison. Radiother Oncol. 2015;
115(3):399–406.
4.
LiuJYuHSunX, et al.
Salvage endoscopic nasopharyngectomy for local recurrent or residual nasopharyngeal carcinoma: a 10-year experience. Int J Clin Oncol. 2017;
22(5):834–842.
5.
WengJWeiJSiJ, et al.
Clinical outcomes of residual or recurrent nasopharyngeal carcinoma treated with endoscopic nasopharyngectomy plus chemoradiotherapy or with chemoradiotherapy alone: a retrospective study. PeerJ. 2017;
5:e3912.
6.
WongEHCLiewYTAbu BakarMZLim EYL, Prepageran N.
A preliminary report on the role of endoscopic endonasal nasopharyngectomy in recurrent rT3 and rT4 nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2017;
274(1):275–281.
7.
CanavanBSalemROSchurginS, et al.
Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab. 2005;
90(10):5779–5785.
8.
LiangWShenGZhangY, et al.
Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment. Chin J Cancer. 2016;
35(1):98.
9.
BianXChenHLiaoL.A retrospective study of salvage surgery for recurrent nasopharyngeal carcinoma. Int J Clin Oncol. 2012;
17(3):212–217.
10.
OngYKSolaresCALeeS, et al.
Endoscopic nasopharyngectomy and its role in managing locally recurrent nasopharyngeal carcinoma. Otolaryngol Clin North Am. 2011;
44(5):1141–1154.
11.
LuTXMaiWYTehBS, et al.
Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2004;
58(3):682–687.
12.
WangYWangZQJiangYX, et al.
A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. Expert Opin Pharmacother. 2016;
17(12):1585–1590.
13.
KaramIHuangSHMcNivenA, et al.
Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience. Head Neck. 2016;
38 (Suppl 1):E1102–E1109.
14.
HuaYJHanFLuLX, et al.
Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J Cancer. 2012;
48(18):3422–3428.
15.
ChuaDTShamJSKwongDLWei WI, Au GK, Choy D.
Locally recurrent nasopharyngeal carcinoma: treatment results for patients with computed tomography assessment. Int J Radiat Oncol Biol Phys. 1998;
41(2):379–386.
16.
ChanJYWeiWI.Impact of resection margin status on outcome after salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma. Head Neck. 2016;
38 (Suppl 1):E594–E599.
17.
PereiraERJonesDJungKPadera TP.
The lymph node microenvironment and its role in the progression of metastatic cancer. Semin Cell Dev Biol. 2015;
38:98–105.
18.
PereiraERKedrinDSeanoG, et al.
Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science. 2018;
359(6382):1403–1407.
19.
LiaoLJHsuWLWangCT, et al.
Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in nasopharyngeal carcinoma: a retrospective study of 180 Taiwanese patients. Clin Otolaryngol. 2018;
43(2):463–469.
20.
AnXDingPRWangFHJiang WQ, Li YH.
Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumor Biol. 2011;
32(2):317–324.
21.
YaoJJZhuFTDongJ, et al.
Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area. BMC Cancer. 2019;
19(1):37.
22.
ProctorMJMcMillanDCMorrisonDSFletcher CD, Horgan PG, Clarke SJ.
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;
107(4):695–699.
23.
ZhaoLChenHHuBZhang H, Lin.
Prognostic significance of Ki67 expression and the derived neutrophil-lymphocyte ratio in nasopharyngeal carcinoma. Cancer Manag Res. 2018;
10:1919–1926.
24.
El-HagAClarkRA.Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol. 1987;
139(7):2406–2413.
25.
GallagherEJLeRoithD.Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care. 2013;
36 (Suppl 2):S233–S239.
26.
MillerBSYeeD.Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res. 2005;
65(22):10123–10127.
27.
HuangPYWangCTCaoKJ, et al.
Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. Eur J Cancer. 2013;
49(8):1923–1931.
28.
GerlachUAAtanasovGWallentaL, et al.
Short-term TNF-alpha inhibition reduces short-term and long-term inflammatory changes post-ischemia/reperfusion in rat intestinal transplantation. Transplantation. 2014;
97(7):732–739.
29.
GacciMSerniSLapiniA, et al.
CXCR3-B expression correlates with tumor necrosis extension in renal cell carcinoma. J Urol. 2009;
181(2):843–848.
30.
AtanasovGSchierleKHauHM, et al.
Prognostic significance of tumor necrosis in hilar cholangiocarcinoma. Ann Surg Oncol. 2017;
24(2):518–525.
31.
SongHWuYRenGGuo W, Wang L.
Prognostic factors of oral mucosal melanoma: histopathological analysis in a retrospective cohort of 82 cases. Histopathology. 2015;
67(4):548–556.
32.
AdamsHJAde KlerkJMHFijnheerRDubois SV, Nievelstein RAJ, Kwee TC.
Prognostic value of tumor necrosis at CT in diffuse large B-cell lymphoma. Eur J Radiol. 2015;
84(3):372–377.
33.
PrasadMLPatelSHoshaw-WoodardS, et al.
Prognostic factors for malignant melanoma of the squamous mucosa of the head and neck. Am J Surg Pathol. 2002;
26(7):883–892.
